Drug access extended for cancer patients who responded well
Disease control
Completed
This study offers continued access to the drug tazemetostat for 58 people with certain cancers who previously benefited from it in other trials. The main goal is to track long-term safety and how long participants stay on the drug. It is not a cure but helps control the disease.
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 17, 2026 04:08 UTC